Lenvatinib plus immunotherapy for advanced cancers with 11q13 amplification
Part of Cancer clinical trials.
This trial tests a combination of two drugs, lenvatinib (a targeted therapy that stops blood vessel growth to tumors) and a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), in people with advanced solid tumors that have a specific genetic change called 11q13 amplification. The goal is to see if this combination can shrink or control tumors that haven't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a locally advanced or metastatic solid tumor that cannot be removed by surgery (like esophageal, head and neck, breast, lung, or liver cancer).
- Your tumor must have a specific genetic change called 11q13 amplification, which is found through a genetic test (NGS).
- You should not have taken lenvatinib before.
- You need to be in good overall condition (able to do daily activities) and have a life expectancy of at least 3 months.
- You must have at least one measurable tumor on a CT scan, and your organs (like liver, kidneys, and bone marrow) must be working adequately.
- You cannot have active autoimmune disease, uncontrolled high blood pressure, or have had major bleeding in the past 4 weeks, and you cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether combining envafolimab (an anti-immune cancer medicine) with lenvatinib (a targeted pill) can shrink or control advanced cancers that have stopped responding to standard care. It may help people whose tumors are not curable with usual treatments, by testing a new combo and finding safe doses.
This Phase 2 study tests whether a combination of lenvatinib and a PD-1/PD-L1–blocking antibody (IBI318) can shrink advanced non-small cell lung cancer and is safe to use. It targets people whose cancer has specific genetic changes or specific prior treatment history, based on three different study groups.
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
This trial tests a combination of three drugs (QL1706, lenvatinib, and chemotherapy) as the first treatment for people with advanced pancreatic cancer that has spread to other parts of the body. It aims to see if this combination is safe and effective.
This trial tests a combination of two drugs, QL1706 and lenvatinib, in people with penile cancer that has already been treated with other therapies. The goal is to see if this new combination can shrink tumors or slow cancer growth.
This trial tests a new combination of lenvatinib (a targeted therapy) plus standard chemotherapy for pancreatic neuroendocrine tumors that have spread to the liveraging after first-line treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.